Stem cell-based culture system for drug development

• US 9,765,297 B2
• Filed: 04/10/2008
• Issued: 09/19/2017
• Est. Priority Date: 04/13/2007
• Status: Active Grant

• Current Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Original Assignee: Trustees Of Columbia University In The City Of New York (Columbia University)
• Inventors: Przedborski, Serge, Wichterle, Hynek, Nagai, Makiko, Jessell, Thomas M.
• Primary Examiner(s): SCHUBERG, LAURA J
• Application Number:
  US12/450,830
• Publication Number:
  US 20100267073A1
• Time in Patent Office: 3,449 Days
• Field of Search: None
• CPC Class Codes: C12N 2502/08 cells of the nervous system
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0619 Neurons

Abstract

The present invention relates to culture systems comprising differentiated stem cells, that may be used for identifying agents useful in treating degenerative nervous system disorders and are suitable for high-throughput screening applications. It is based, at least in part, on the discovery that co-cultures of (i) astrocytes expressing a mutated SODI gene and (ii) stem-cell derived motor neurons manifested cell death via a Bax-dependent mechanism, and modeled motor neuron death in amyotrophic lateral sclerosis.

Claims

1. A method for identifying an agent for treating a neurodegenerative condition associated with degeneration of motor neurons caused by soluble factors released by astrocytes carrying a SOD1 G93A mutation, comprising:

i. subjecting embryonic stem cells to retinoic acid and sonic hedgehog agonist in vitro, for five days, to produce a-motor neuron cells;

ii. plating the motor neuron cells in neurobasal medium containing 2% heat inactivated horse serum, B27 supplement, 0.5 mM glutamine, 25 μ

M 2-mercaptoethanol, and penicillin/streptomycin and adding a degeneration-promoting astrocyte carrying a SOD1 G93A mutation or a conditioned medium produced by a culture of degeneration-promoting astrocytes carrying a SOD1 G93A mutation, so as to establish a culture system comprising the motor neuron and a degeneration-promoting astrocyte carrying a SOD1 G93A mutation or a conditioned medium produced by a culture of degeneration-promoting astrocytes carrying a SOD1 G93A mutation;

iii. adding the agent to the culture system;

iv. subjecting the culture system to a time period of culturing of at least 2 days;

v. evaluating whether the motor neuron in the culture system degenerates in the presence of the agent, wherein the evaluation of degeneration is relative to a control culture system comprising identically produced motor neurons subjected to the same time period of culturing in the absence of the agent; and

vi. determining if the agent reduces degeneration of the motor neurons by comparing the number of dead neurons present in the culture system containing the agent to the number of dead neurons in the control culture system.

2. The method of claim 1, wherein the embryonic stem cell and degeneration-promoting astrocyte are from a mouse.

3. A method for identifying an agent for treating amyotrophic lateral sclerosis caused by soluble factors released by astrocytes carrying a SOD1 G93A mutation, comprising:

i. subjecting embryonic stem cells to retinoic acid and sonic hedgehog agonist in vitro, for five days, to produce a-motor neuron cells;

ii. plating the motor neuron cells in neurobasal medium containing 2% heat inactivated horse serum, B27 supplement, 0.5 mM glutamine, 25 μ

M 2-mercaptoethanol, and penicillin/streptomycin and adding a degeneration-promoting astrocyte carrying a SOD1 G93A mutation or a conditioned medium produced by a culture of degeneration-promoting astrocytes carrying a SOD1 G93A mutation, so as to establish a culture system comprising the motor neuron and a degeneration-promoting astrocyte carrying a SOD1 G93A mutation or a conditioned medium produced by a culture of degeneration-promoting astrocytes carrying a SOD1 G93A mutation;

iii. adding the agent to the culture system;

iv. subjecting the culture system to a time period of culturing of at least 2 days;

v. evaluating whether the motor neuron in the culture system degenerates in the presence of the agent, wherein the evaluation of degeneration is relative to a control culture system comprising identically produced motor neurons subjected to the same time period of culturing in the absence of the agent; and

vi. determining if the agent reduces degeneration of the motor neurons by comparing the number of dead neurons present in the culture system containing the agent to the number of dead neurons in the control culture system.

4. The method of claim 3, wherein the degeneration-promoting astrocyte was obtained from an individual suffering from amyotrophic lateral sclerosis.